Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China’s growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to __________ Commission file number 001-31392 PLURI INC. (Exact name of registrant as specified in its charter) | Nevada | 98-0351734 | | --- | --- | | (State or other jurisdict ...

Core Insights - Pluri, Inc. has completed the first phase of its program with Resbiomed Technologies, focusing on developing placenta-derived biomaterials for regenerative medicine [1][2][3] Company Overview - Pluri is a biotechnology company specializing in scalable cell-based solutions and has a strong focus on regenerative medicine, foodtech, and agtech [7] - The company operates a contract development and manufacturing division, PluriCDMO™, which provides advanced manufacturing services [8] Collaboration Details - The partnership with Resbiomed aims to enhance the production of placenta-derived biomaterials, leveraging Pluri's proprietary processing capabilities [2][3] - The first phase involved initial process development and feasibility, with plans to advance to further phases focusing on process definition and manufacturing readiness [2][5] Market Potential - Human collagen and collagen-rich materials are in high demand due to their stringent quality requirements, and scalable production could expand access across various medical applications [4] - The collaboration is seen as a response to the growing demand for PluriCDMO services among companies developing next-generation cell and tissue-based technologies [5] Leadership Statements - The CEO of Pluri expressed confidence in the collaboration, highlighting its potential to accelerate programs and support commercialization efforts [6] - The CEO of Resbiomed emphasized the importance of partnering with an experienced manufacturer to ensure scalable supply and consistent quality [6]

Core Insights - Pluri, Inc. has expanded its manufacturing agreement with Remedy Cell Ltd., focusing on stem cell-derived, cell-free therapeutics for fibrotic conditions [1][4] Group 1: Collaboration and Achievements - The collaboration has successfully integrated Remedy Cell's proprietary manufacturing process into Pluri's GMP facility, completing training and qualification for the manufacturing team [2][3] - Several clinical-grade batches of Remedy Cell's lead candidate have been manufactured, intended for use in an initial Phase 1b clinical trial, marking significant progress in clinical development [2][3] Group 2: Future Plans and Commitment - PluriCDMO™ will continue to provide manufacturing and process-development support as Remedy Cell advances its clinical and pre-commercial programs, highlighting the productive partnership [4] - Both companies express a strong commitment to advancing next-generation, cell-free biologics to address unmet medical needs [4][5] Group 3: Company Backgrounds - Pluri is a biotechnology company specializing in scalable cell-based solutions and has a strong intellectual property portfolio, focusing on regenerative medicine and CDMO services [6] - Remedy Cell is a clinical-stage biopharmaceutical company developing innovative therapies for fibrotic diseases, with its lead product RC-0315 showing potential in treating Idiopathic Pulmonary Fibrosis (IPF) [8][9]

Core Viewpoint - Pluri Inc. has appointed Alejandro Weinstein as Chairman of the Board, aiming to strengthen its market position and unlock the value of its assets [1][2][4]. Leadership Transition - Alejandro Weinstein, a significant shareholder, will lead the company into its next growth phase, emphasizing strategic changes and value creation [2][4]. - Zami Aberman, the outgoing Chairman, will transition to Vice Chairman, continuing to support the company's strategic direction [3][4]. Financial Transactions - Pluri has entered into a Securities Purchase Agreement with Weinstein, involving the purchase of 625,000 common shares and warrants for a total of $2.5 million, intended for general working capital [4][6]. - The warrants have an exercise price of $4.25 per share and are exercisable until June 30, 2026 [4]. Shareholder Dynamics - Weinstein's ownership is expected to rise to approximately 30% of the issued and outstanding shares, reflecting his confidence in Pluri's asset base and long-term strategy [6]. Company Overview - Pluri Inc. is a biotechnology company focused on mass-scale cell expansion and biofarming, utilizing a patented 3D cell expansion platform [8]. - The company operates in regenerative medicine, foodtech, and agtech, aiming to address global challenges such as sustainable food production and healthcare [9].

Core Insights - Pluri Inc. has received multiple awards recognizing its innovation and leadership in biotechnology, particularly in cell-based solutions for agriculture and sustainable food systems [1][2][4] Group 1: Awards and Recognitions - Pluri was named Overall BioAgriculture Company of the Year by the Biotech Breakthrough Awards, highlighting its advancements in applying cell therapy to agriculture [2] - The company won the 2024 Egalitarian Employment Award in the Large Company category from Israel's Ministry of Labor, Social Affairs and Social Services, with a government grant of 40,000 NIS expected alongside the award [3] - Pluri's subsidiaries, Coffeesai Ltd. and Kokomodo Ltd., received significant industry awards for their innovative approaches in sustainable food production and climate-resilient agriculture [7] Group 2: Company Position and Strategy - Pluri is positioned as a leader in biotechnology, developing patented technologies that have the potential to transform various industries, including regenerative medicine and agtech [4] - The company's proprietary 3D cell expansion platform enables scalable production of cell-based products, facilitating partnerships in multiple sectors [4][5] - The CEO emphasized the strength and versatility of Pluri's platform, reflecting market confidence in its strategy to apply cell-based innovation across industries [5]

Financial Performance - Revenues for the three-month period ended September 30, 2025, were $316,000, a decrease of 3% compared to $326,000 for the same period in 2024[87]. - Net loss for the three-month period ended September 30, 2025, was $6,132,000, compared to a net loss of $6,036,000 for the same period in 2024, primarily due to increased R&D and administrative expenses[93]. - Loss per share for the three-month period ended September 30, 2025, was $0.65, a decrease from $1.08 loss per share in the same period of 2024, attributed to an increase in the weighted average number of shares outstanding[94]. Expenses - Cost of revenues increased by 59% from $126,000 in the three-month period ended September 30, 2024, to $201,000 in the same period of 2025, primarily due to higher personnel costs[88]. - R&D expenses, net, rose by 36% from $2,889,000 for the three-month period ended September 30, 2024, to $3,931,000 in 2025, attributed to increased salaries and new employee additions following the acquisition of Kokomodo[89]. - General and administrative expenses increased by 1% from $2,509,000 in the three-month period ended September 30, 2024, to $2,534,000 in 2025, mainly due to higher share-based compensation expenses[90]. Business Developments - The company launched a new business division, PluriCDMO™, in January 2024, offering cell therapy manufacturing services and generating revenues from several client agreements[77]. - The company completed the acquisition of approximately 79% of Kokomodo, an innovative agfood startup, on April 28, 2025, to enhance its capabilities in sustainable cacao production[80]. - In June 2024, Ever After Foods raised $10 million in a funding round to support its B2B technology platform for cultivated meat, with Pluri Biotech investing $1.25 million[83]. Strategic Initiatives - The company is actively pursuing collaborations in AgTech, including partnerships to enhance bio stimulant delivery and develop cell-cultured coffee and cacao[78][79]. - The company aims to expand its technology applications across various industries, including regenerative medicine, food technology, and agriculture technology[70]. - The company is focused on developing placenta-based cell therapy product candidates for inflammatory and hematologic conditions, as well as launching a novel immunotherapy platform utilizing MAIT cells[72][75]. Financial Position - Total current assets as of September 30, 2025, were $16,921,000, while total current liabilities were $32,160,000, resulting in a working capital deficit of $15,239,000[96]. - Cash used in operating activities increased to $5,428,000 during the three months ended September 30, 2025, compared to $4,064,000 in the same period of 2024[98]. - Cash provided by investing activities was $3,850,000 for the three months ended September 30, 2025, compared to $585,000 in the same period of 2024[99]. - As of September 30, 2025, cash and cash equivalents totaled $4,687,000, an increase from $3,563,000 as of September 30, 2024[97]. Liquidity and Going Concern - The company has accumulated a deficit of $448,905,000 since inception and does not anticipate generating significant revenues from product sales in the next twelve months[117]. - The company is addressing liquidity issues by implementing initiatives to continue operations, with cash balances totaling $16,393,000 as of September 30, 2025[118]. - Management estimates insufficient resources to meet operating obligations for at least twelve months from the issuance date of the financial statements, raising substantial doubt about the company's ability to continue as a going concern[120]. - The company received a total of $2.3 million in funding under the NIAID contract before its termination on April 15, 2025[109].

Core Insights - Pluri Inc. has launched a wholly-owned subsidiary, Cellav Health and Aesthetics Ltd., focusing on regenerative solutions using its proprietary 3D cell expansion platform [1][6] - Cellav has secured a commercial collaboration with Miss Universe Skincare to co-develop a new line of advanced, cell-based skincare products [1][2] - The first product from this collaboration is expected to launch in the first half of 2026, leveraging Miss Universe Skincare's global distribution platform [2][6] Company Overview - Cellav aims to transform cutting-edge cell science into impactful solutions for health and aesthetics, bridging science with real-world results [5][7] - The subsidiary will operate in three core areas: developing premium cell-derived ingredients, offering professional-use and consumer-ready products, and providing a flexible technology platform for partners [7] - Cellav's offerings are backed by over two decades of Pluri's expertise in pharmaceutical-grade development [7] Market Potential - The beauty market, where Cellav is expanding, is projected to reach $194.05 billion by 2032, indicating significant growth opportunities [6] - The collaboration with Miss Universe Skincare is seen as a strategic move to tap into high-growth, revenue-generating markets [2][4] Leadership and Vision - Cellav is led by CEO Katty Dowery, who has extensive experience in cell-based technologies and regenerative medicine [3][4] - The company emphasizes scientific integrity and high-quality standards, aiming to make regenerative science accessible and impactful in the beauty industry [4][5]

Core Insights - Pluri, Inc. has entered significant international collaborations through its foodtech and agtech subsidiaries, marking a major advancement in its mission to transform food and agriculture production using advanced 3D cell-expansion technology [1][2][3] Company Overview - Pluri operates three subsidiaries: Ever After Foods, Kokomodo, and Coffeesai, which have signed collaboration agreements with global leaders in food and agtech across Asia, Europe, and the U.S. This expansion indicates increasing commercial viability and global demand for sustainable, cell-based innovations [2][4] - The collaborations are anchored by a minimum-viable-product (MVP) funded by leading global players, showcasing substantial commitment and trust in the innovative potential of these partnerships [4] Subsidiary Developments - Ever After Foods is advancing scale-up validation and pre-commercial trials with food companies, focusing on turning pipeline projects into pilot results while maintaining a capital-efficient business model [5] - Kokomodo has signed strategic agreements with a European food innovation firm and a U.S.-based multinational, aiming to enhance its research, development, and manufacturing capabilities in the cacao industry [5] - Coffeesai has entered a collaboration with a major East Asian food and beverage conglomerate to accelerate eco-friendly coffee production through cell-based cultivation, minimizing the environmental impact of traditional farming [5] Market Context - The momentum of Pluri's initiatives comes at a time of rising demand for sustainable solutions in agriculture, driven by challenges such as climate change, dwindling natural resources, and a growing global population [3][4] - Pluri's proprietary 3D cell expansion platform enables rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints, addressing global challenges in sustainable food production and climate resilience [6]

Core Insights - Pluri Inc. is recognized as a promising long-term penny stock with significant upside potential, particularly following its recent collaboration with a Mexican public body to advance cell-based coffee manufacturing [1][3]. Group 1: Collaboration and Innovation - Pluri's subsidiary, Coffeesai Ltd., has entered into a collaboration agreement with Instituto del Café de Chiapas/INCAFECH to promote cell-based coffee production in Chiapas, Mexico, which is known as the leading coffee-growing region in the country [1][2]. - The partnership aims to establish Chiapas as a hub for innovation in coffee manufacturing, leveraging state support to enhance the commercialization of cell-based coffee products [1][2]. Group 2: Business Model and Revenue Generation - Coffeesai utilizes Pluri's proprietary 3D cell expansion platform and two decades of expertise to develop sustainable cell-based coffee products, outlining a multi-phase, capital-light roadmap to mitigate commercialization risks [2][3]. - The collaboration is expected to create shareholder value through potential non-dilutive revenues from licensing and technology transfer, as well as recurring revenue streams from royalty-bearing models and joint ventures [3]. Group 3: Company Overview - Pluri Inc. is a biotechnology company focused on researching, developing, and manufacturing cell-based products and related technologies across various industries [4].